DMG mice treated with BMI1 inhibitors showed prolonged survival. Concurrent treatment with a BMI1 inhibitor and a BH3 mimetic led to a sustained anti-tumor response, even one week after therapy was ended. Here, BMI1 is linked to neoplasm.